{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Akari Therapeutics Announces Private Placement - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"8lzfjGXkn8\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-private-placement\/\">Akari Therapeutics Announces Private Placement<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-private-placement\/embed\/#?secret=8lzfjGXkn8\" width=\"600\" height=\"338\" title=\"&#8220;Akari Therapeutics Announces Private Placement&#8221; &#8212; Market Newsdesk\" data-secret=\"8lzfjGXkn8\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"NEW YORK\u00a0and\u00a0LONDON, July 07, 2021 (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc\u00a0(Nasdaq: AKTX) (\u201cAkari\u201d or the \u201cCompany\u201d), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and\/or leukotriene systems are implicated, today announced that it has entered into definitive securities purchase agreements with certain accredited and institutional investors, led by existing investors of the Company, including Dr.\u00a0Ray Prudo, the Company\u2019s Chairman, to receive gross proceeds of\u00a0approximately $12 million through a private placement of its equity securities. In connection with the offering, the Company will issue unregistered American Depository Shares, each representing 100 of the Company\u2019s ordinary shares (\u201cADSs\u201d), at a purchase price of\u00a0$1.55\u00a0per ADS. The closing of the offering is expected to take &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjY0MSM0Mjg1NjE5IzIwMjAyNjM="}